Table 1.
Baseline Demographic and Clinical Characteristics of Adult Trial Patients: Jos University Teaching Hospital and Comprehensive Health Centre Zamko
| Characteristic | JUTH Adult |
CHCZ Adult |
Total Adult |
P Value,b JUTH vs CHCZ | |||
|---|---|---|---|---|---|---|---|
| POC (N = 148), n (%)a | SOC (N = 145), n (%) | POC (N = 102), n (%) | SOC (N = 101), n (%) | POC (N = 250), n (%) | SOC (N = 246), n (%) | ||
| Age, median (IQR), years | 38 (31–45) | 37 (30–42) | 33 (29–40) | 35 (30–43) | 36 (30–43) | 36 (30– 42) | |
| 18–29 | 28 (18.9) | 31 (21.4) | 28 (27.5) | 24 (23.8) | 56 (22.4) | 55 (22.4) | .079 |
| 30–35 | 35 (23.6) | 35 (24.1) | 30 (29.4) | 31 (30.7) | 65 (26.0) | 66 (26.8) | |
| 36–42 | 34 (23.0) | 44 (30.3) | 26 (25.5) | 20 (19.8) | 60 (24.0) | 64 (26.0) | |
| >42 | 51 (34.5) | 35 (24.1) | 18 (17.6) | 26 (25.7) | 69 (27.6) | 61 (24.8) | |
| Female sex (vs male) | 88 (59.5) | 92 (63.4) | 76 (74.5) | 70 (69.3) | 164 (65.6) | 162 (65.9) | .016 |
| Education | |||||||
| None | 14 (9.5) | 10 (6.9) | 55 (53.9) | 57 (56.4) | 69 (27.6) | 67 (27.2) | <.001* |
| Primary | 43 (29.1) | 33 (22.8) | 22 (21.6) | 21 (20.8) | 65 (26.0) | 54 (22.0) | |
| Secondary | 43 (29.1) | 43 (29.7) | 23 (22.5) | 20 (19.8) | 66 (26.4) | 63 (25.6) | |
| Tertiary | 48 (32.4) | 59 (40.7) | 2 (2.0) | 3 (3.0) | 50 (20.0) | 62 (25.2) | |
| Employment | |||||||
| Nonincome-generating | 34 (23.0) | 31 (21.4) | 12 (14.3) | 13 (15.1) | 46 (19.8) | 44 (19.1) | <.001* |
| Labor/service/trade | 87 (58.8) | 86 (59.3) | 69 (82.1) | 72 (83.7) | 156 (67.2) | 158 (68.4) | |
| Professional/manageria1 | 27 (18.2) | 28 (19.3) | 3 (3.6) | 1 (1.2) | 30 (12.9) | 29 (12.6) | |
| Marital status | |||||||
| Single | 44 (29.7) | 43 (29.7) | 18 (17.6) | 14 (13.9) | 62 (24.8) | 57 (23.2) | .001 |
| Married | 77 (52.0) | 69 (47.6) | 61 (59.8) | 57 (56.4) | 138 (55.2) | 126 (51.2) | |
| Divorced/separated | 13 (8.8) | 18 (12.4) | 16 (15.7) | 20 (19.8) | 29(11.6) | 38 (15.5) | |
| Widowed | 14 (9.5) | 15 (10.3) | 7 (6.9) | 10 (9.9) | 21 (8.4) | 25 (10.2) | |
| World Health Organization clinical stage | |||||||
| 1 | 91 (61.9) | 97 (67.4) | 73 (71.6) | 69 (68.3) | 164 (65.9) | 166 (67.8) | .017* |
| 2 | 28 (19.0) | 24 (16.7) | 19 (18.6) | 23 (22.8) | 47 (18.9) | 47 (19.2) | |
| 3 | 27 (18.4) | 21 (14.6) | 8 (7.8) | 7 (6.9) | 35 (14.1) | 28 (11.4) | |
| 4 | 1 (0.7) | 2 (1.4) | 2 (2.0) | 2 (2.0) | 3(1.2) | 4 (1.6) | |
| Tuberculosis coinfection | 14 (9.5) | 10 (6.9) | 3 (2.9) | 0 (0.0) | 17 (6.8) | 10 (4.1) | .001* |
| Body mass index, median (IQR), kg/m2 | 21.2 (19.3–24.2) | 21.0 (18.7–25.2) | 20.4 (18.3–23.2) | 20.4 (18.0–23.4) | 21.0 (18.8–23.7) | 20.9 (18.5–24.0) | |
| Underweight (<18.5) | 25 (17.7) | 31 (22.6) | 24 (27.3) | 23 (28.4) | 49 (21.4) | 54 (24.8) | .003* |
| Normal (18.5–24.9) | 92 (65.2) | 71 (51.8) | 58 (65.9) | 47 (58.0) | 150 (65.5) | 118 (54.1) | |
| Overweight (25.0–29.9) | 18 (12.8) | 26 (19.0) | 5 (5.7) | 11 (13.6) | 23 (10.0) | 37 (17.0) | |
| Obese (≥30.0) | 6 (4.3) | 9 (6.6) | 1 (1.1) | 0 (0.0) | 7(3.1) | 9 (4.1) | |
| Viral load, median (IQR), copies/mL | 95 922 (17 748–301 519) | 121 850 (20919–362 895) | 113 416 (17369–453 136) | 80 322 (22 839–417 132) | 106 347 (17 748–342 093) | 99 836 (21 810–394 839) | |
| <10 000 | 29 (19.6) | 26 (18.2) | 21 (21.0) | 17 (18.5) | 50 (20.2) | 43 (18.3) | .855 |
| 10 000–99 999 | 45 (30.4) | 42 (29.4) | 27 (27.0) | 33 (35.9) | 72 (29.0) | 75 (31.9) | |
| 100 000–999 999 | 64 (43.2) | 59 (41.3) | 41 (41.0) | 33 (35.9) | 105 (42.3) | 92 (39.2) | |
| ≥1 000000 | 10(6.8) | 16(11.2) | 11(11.0) | 9(9.8) | 21(8.5) | 25(10.6) | |
| Initial antiretroviral therapy regimen | |||||||
| ABC-3TC-DTG | 1 (0.7) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 1 (0.4) | 1 (0.4) | .009* |
| ABC-3TC-EFV | 2 (1.4) | 4 (2.8) | 0 (0.0) | 0 (0.0) | 2 (0.8) | 4 (1.6) | |
| AZT-3TC-NVP | 0 (0.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 1 (0.4) | 0 (0.0) | |
| TDF-3TC-DTG | 46 (31.1) | 47 (32.4) | 26 (25.5) | 22 (21.8) | 72 (28.8) | 69 (28.1) | |
| TDF-3TC-EFV | 99 (66.9) | 93 (64.1) | 75 (73.5) | 79 (78.2) | 174 (69.6) | 172 (69.9) | |
Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; CHCZ, Comprehensive Health Centre Zamko; DTG, dolutegravir; EFV, efavirenz; IQR, interquartile range; JUTH, Jos University Teaching Hospital; NVP, nevirapine; POC, point of care; SOC, standard of care; TDF, tenofovir.
a
Values shown are n (%) unless otherwise indicated; % is of those with recorded value.
b
The χ2 test or Fisher exact test was used for frequencies ≤5 (asterisked) to obtain P values for comparisons between the JUTH and CHCZ clinics.